Skip to main content

Dosing

Evan B.
Actual Nurtec ODT patient.

*Per IQVIA as oral brand in class (oral CGRP receptor antagonists): number one prescribed and number one in new prescriptions, since 8/6/21. Data current as of 8/21/23.

One medication in a 75 mg dose puts the power to treat or prevent in your patient's hands1

TREATING MIGRAINE ATTACKS

One 75 mg ODT, as needed, for the acute treatment of migraine with or without aura.1

PREVENTING MIGRAINE ATTACKS

One 75 mg ODT every other day for the preventive treatment of episodic migraine.1

24h

24-hour max:
one 75 mg ODT

  • A non-CGRP acute treatment can be used on days when Nurtec ODT is taken, if needed.2
  • Nurtec ODT has a Tmax  of 1.5 hours.1
  • The half-life of Nurtec ODT is 11 hours.1 
  • The safety of using more than 18 doses in a 30-day period has not been established.1
Double up image

PRESCRIBE TO MEET YOUR PATIENTS’ INDIVIDUAL NEEDS EACH MONTH1

Nurtec ODT 75 mg is available in blister packs of 8 tablets each. For acute treatment, as-needed dosing, you can prescribe one 8-pack, or double up to two 8-packs in one monthly prescription.1,*

I take one dose of Nurtec ODT, it dissolves in seconds and gets me back to what I love.

Corinne S.

Actual Nurtec ODT patient.
Individual results may vary.

I am able to get quick pain relief and get back to normal function when a migraine attacks, in just one dose.

Alexandra N.

Actual Nurtec ODT patient.
Individual results may vary.

Patients were invited to share their experiences on Nurtec ODT. All content was accurate at the time of publication.

One dosage strength. Anytime. Anywhere.1,*

The only CGRP receptor antagonist available as an orally disintegrating tablet1,3

Can be taken up to
once daily as needed.
No water necessary.1,†

No restrictions for
patients taking oral
contraceptives or
antidepressants.1,4,5

Shown to both treat and prevent migraine attacks.1

Not contraindicated in patients with stable
cardiovascular disease or risk factors.1,6

CGRP=calcitonin gene-related peptide
*Store Nurtec ODT at controlled room temperature, 20°C to 25°C (68°F to 77°F); with excursions permitted between 15°C to 30°C (59°F to 86°F).1
The safety of using more than 18 doses in a 30-day period has not been established.1

Instructing patients on how to take Nurtec ODT

READY

Instruct patients as follows:

  • With dry hands, open the blister pack and peel back the foil over one tablet. Do not push it through the foil.1
  • Gently remove Nurtec ODT from the blister pack immediately before taking, and do not store it for future use.1

No titration needed.1

SET

Patients can place Nurtec ODT on or under their tongue and it dissolves within seconds—no water needed.1,7

GO

A single 75 mg tablet can be taken daily for acute treatment and every other day for preventive treatment.1

References: 1. Nurtec ODT. Package insert. Pfizer Inc. 2. Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2020;397(10268): 51-60. doi: 10.1016/S0140-6736(20)32544-7 3. Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally dissolving tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737-745. doi:10.1016/S0140-6736(19)31606-X 4. Hutchinson S, Schim J, Lipton RB, et al. Rimegepant is safe and tolerable for the acute treatment of migraine in patients using preventive migraine medications: Results from a long-term open-label safety study (study 201). Poster presented at: Virtual Annual Scientific Meeting of the American Headache Society; June 13, 2020. 5. Baskin SM, Buse DC, Jensen CM, et al. Rimegepant 75 mg is safe and well tolerated for the acute treatment of migraine in adults using selective serotonin reuptake inhibitors and other antidepressants: Results from a long-term open-label safety study (study 201). Poster presented at: Virtual Annual Scientific Meeting of the American Headache Society; June 13, 2020. 6. Data on File. RIM130. Pfizer Inc. 7. Abay FB, Ugurlu T. Orally disintegrating tablets: a short review. J Pharm Drug Devel. 2015;3(3):303-311. doi: 10.15744/2348-9782.3.303